Arab Finance: GlaxoSmithKline Egypt (GSK Egypt) recorded consolidated net profits attributable to the controlling interest of EGP 125.003 million in the first nine months of 2026, 313.81% year-on-year (YoY) higher than EGP 30.207 million, according to the financial results.
On the other hand, net sales fell to EGP 2.869 billion at the end of September from EGP 2.893 billion.
Meanwhile, earnings per share (EPS) grew to EGP 1.35 in the nine months of 2026 from EGP 0.33 in the year-ago period.
Regarding the standalone income statements, net profits jumped to EGP 122.289 million from EGP 36.001 million, while EPS grew to EGP 1.32 from EGP 0.39.
Established in 1981, the company manufactures branded and generic drugs, chemicals, veterinary products, vitamins and nutritional products, and pharmaceutical and bulk drug substances. GSK Egypt focuses on a number of key therapeutic areas that include primary care, specialty, and respiratory care. The company was incorporated in 1981 in Cairo and was listed on the Egyptian Exchange (EGX) in 1985.